Dishman Pharmaceuticals & Chemicals (DPCL) has posted disappointing results for the Q4FY10 due to 24%YoY fall in CRAMS revenues. Total income declined by 13%YoY from Rs2.89bn to Rs2.50bn due to the slowdown in Carbogen Amcis (CA) and other CRAMS business. Net profit declined by 71% from Rs717m to Rs211m.
The company’s EBIDTA margin improved by 560bps from 24.2% to 29.8% mainly (more…)